|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AHI1 |
Gene summary for AHI1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AHI1 | Gene ID | 54806 |
| Gene name | Abelson helper integration site 1 | |
| Gene Alias | AHI-1 | |
| Cytomap | 6q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q8N157 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54806 | AHI1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.65e-23 | -7.48e-01 | 0.0155 |
| 54806 | AHI1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.66e-12 | -6.85e-01 | -0.1808 |
| 54806 | AHI1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.89e-03 | -8.20e-01 | 0.0216 |
| 54806 | AHI1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.35e-02 | -4.44e-01 | -0.0811 |
| 54806 | AHI1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.40e-09 | -7.60e-01 | -0.1207 |
| 54806 | AHI1 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.36e-03 | -5.68e-01 | -0.1526 |
| 54806 | AHI1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.33e-13 | -4.78e-01 | -0.1464 |
| 54806 | AHI1 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.62e-15 | -4.86e-01 | -0.1001 |
| 54806 | AHI1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.21e-03 | -6.93e-01 | -0.2061 |
| 54806 | AHI1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.96e-03 | -5.80e-01 | -0.0179 |
| 54806 | AHI1 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.58e-13 | -6.06e-01 | 0.096 |
| 54806 | AHI1 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.87e-02 | -5.86e-01 | 0.0528 |
| 54806 | AHI1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.33e-09 | -6.67e-01 | 0.0338 |
| 54806 | AHI1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.57e-10 | -3.80e-01 | 0.0674 |
| 54806 | AHI1 | HTA11_6818_2000001011 | Human | Colorectum | AD | 1.21e-02 | -6.08e-01 | 0.0112 |
| 54806 | AHI1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.29e-03 | -5.33e-01 | 0.0588 |
| 54806 | AHI1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.10e-14 | -4.14e-01 | 0.294 |
| 54806 | AHI1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.04e-04 | -3.10e-01 | 0.3859 |
| 54806 | AHI1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.57e-04 | -6.30e-01 | 0.2585 |
| 54806 | AHI1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.86e-22 | -6.01e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00485685 | Prostate | Tumor | embryonic organ development | 93/3246 | 427/18723 | 9.84e-03 | 4.18e-02 | 93 |
| GO:00016541 | Prostate | Tumor | eye development | 82/3246 | 371/18723 | 1.02e-02 | 4.27e-02 | 82 |
| GO:000209011 | Prostate | Tumor | regulation of receptor internalization | 17/3246 | 56/18723 | 1.17e-02 | 4.81e-02 | 17 |
| GO:003010020 | Thyroid | PTC | regulation of endocytosis | 108/5968 | 211/18723 | 3.92e-09 | 1.04e-07 | 108 |
| GO:004580720 | Thyroid | PTC | positive regulation of endocytosis | 58/5968 | 100/18723 | 6.11e-08 | 1.28e-06 | 58 |
| GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
| GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
| GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
| GO:0006898110 | Thyroid | PTC | receptor-mediated endocytosis | 112/5968 | 244/18723 | 2.87e-06 | 3.74e-05 | 112 |
| GO:006056219 | Thyroid | PTC | epithelial tube morphogenesis | 141/5968 | 325/18723 | 7.52e-06 | 8.73e-05 | 141 |
| GO:004825918 | Thyroid | PTC | regulation of receptor-mediated endocytosis | 55/5968 | 110/18723 | 5.64e-05 | 4.99e-04 | 55 |
| GO:004311219 | Thyroid | PTC | receptor metabolic process | 77/5968 | 166/18723 | 6.21e-05 | 5.47e-04 | 77 |
| GO:004826017 | Thyroid | PTC | positive regulation of receptor-mediated endocytosis | 30/5968 | 52/18723 | 1.06e-04 | 8.56e-04 | 30 |
| GO:007207316 | Thyroid | PTC | kidney epithelium development | 60/5968 | 136/18723 | 1.78e-03 | 9.66e-03 | 60 |
| GO:00720067 | Thyroid | PTC | nephron development | 61/5968 | 142/18723 | 3.49e-03 | 1.69e-02 | 61 |
| GO:00017389 | Thyroid | PTC | morphogenesis of a polarized epithelium | 41/5968 | 94/18723 | 1.10e-02 | 4.38e-02 | 41 |
| GO:0030100111 | Thyroid | ATC | regulation of endocytosis | 113/6293 | 211/18723 | 1.71e-09 | 4.22e-08 | 113 |
| GO:000182222 | Thyroid | ATC | kidney development | 146/6293 | 293/18723 | 5.81e-09 | 1.28e-07 | 146 |
| GO:000165522 | Thyroid | ATC | urogenital system development | 164/6293 | 338/18723 | 7.92e-09 | 1.70e-07 | 164 |
| GO:007200122 | Thyroid | ATC | renal system development | 149/6293 | 302/18723 | 9.48e-09 | 1.99e-07 | 149 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AHI1 | SNV | Missense_Mutation | c.3220N>A | p.Arg1074Ser | p.R1074S | Q8N157 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| AHI1 | SNV | Missense_Mutation | rs774732509 | c.3565N>C | p.Gly1189Arg | p.G1189R | Q8N157 | protein_coding | tolerated_low_confidence(0.25) | possibly_damaging(0.448) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| AHI1 | SNV | Missense_Mutation | c.1723G>A | p.Glu575Lys | p.E575K | Q8N157 | protein_coding | tolerated(0.18) | possibly_damaging(0.628) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| AHI1 | SNV | Missense_Mutation | c.1231A>G | p.Lys411Glu | p.K411E | Q8N157 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| AHI1 | SNV | Missense_Mutation | novel | c.1467N>A | p.Asn489Lys | p.N489K | Q8N157 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AHI1 | SNV | Missense_Mutation | c.974N>G | p.Glu325Gly | p.E325G | Q8N157 | protein_coding | deleterious(0) | benign(0.255) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| AHI1 | SNV | Missense_Mutation | c.303G>C | p.Leu101Phe | p.L101F | Q8N157 | protein_coding | tolerated(0.14) | benign(0.172) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| AHI1 | SNV | Missense_Mutation | c.2440C>T | p.Arg814Cys | p.R814C | Q8N157 | protein_coding | tolerated(0.1) | benign(0.173) | TCGA-D8-A1JB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| AHI1 | insertion | Frame_Shift_Ins | novel | c.1465_1466insCTCCTGCTTT | p.Asn489ThrfsTer19 | p.N489Tfs*19 | Q8N157 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| AHI1 | SNV | Missense_Mutation | rs199612496 | c.82C>T | p.Arg28Cys | p.R28C | Q8N157 | protein_coding | tolerated(0.07) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |